Other genomic alterations related to SWI/SNF complexes, which are rarely found in gynecological cancers, have also been proposed to have predictive value for immunotherapy in malignant tumors; these include polybromo-1, SMARCB1, and SMARCA4 loss, among others (53, 54). Here, SMARCA1 is linked to cancer.